Mounjaro Beats Ozempic for Weight Loss

Key Takeaways

• A new large-scale study found that the diabetes medication Mounjaro (tirzepatide) outperformed Ozempic for weight loss.
• Mounjaro may be more effective because it incorporates a gastrointestinal hormone that impacts insulin sensitivity and brain signals that relay feeling full.
• Which drug you take should be determined with your healthcare provider and possibly an obesity medicine specialist.

Since Ozempic (semaglutide) came out of the gate after the U.S. Food and Drug Administration's approval in 2017, it has become a blockbuster medication for treating type 2 diabetes .

Arriving on the market about four years later, the diabetes medication Mounjaro (tirzepatide) - which is in the same class of GLP-1 drugs as Ozempic - has been steadily gaining traction.

In addition to being effective in controlling diabetes, both medications have been proven to produce significant weight loss in patients.

A large new study published in JAMA Internal Medicine , however, suggests that tirzepatide may outperform semaglutide when it comes to shedding pounds.

Chances of Losing Weight Increases Over Time

Based on analysis of electronic health record data from more than 18,000 overweight or obese adults who were taking either one of the two drugs, researchers on the JAMA study found that those on tirzepatide were nearly twice as likely to achieve 5 percent weight loss, about two and a half times more likely to lose 10 percent of their body weight, and more than three times as likely to reach 15 percent weight loss.

After one year of treatment, weight loss of at least 5 percent was reached by nearly 82 percent of tirzepatide users compared with 66.5 percent of semaglutide users. About 62 percent of participants who took tirzepatide versus 37 percent of those on semaglutide achieved at least 10 percent weight loss, and 42 percent of those on tirzapatide lost 15 percent or more of their body weight compared with 18 percent in the semaglutide group.

Patients on tirzepatide also experienced significantly larger reductions in body weight over time.

At three months, individuals on tirzepatide saw an average body weight drop of 6 percent compared with less than 4 percent for those who took semaglutide. By one year, however, the weight loss difference was almost twice as great, with an average loss of 15 percent for tirzepatide and 8 percent for semaglutide.

"I would say that based on study results, tirzepatide is currently the best for weight loss, but semaglutide works really well, too," says Sun Kim, MD, an endocrinologist who specializes in the treatment of type 2 diabetes and is an associate professor of medicine at Stanford University in California. "Some patients don't do as well on one drug compared to the other. They both function really well, but one may have better results."

What's Behind the Difference?

Both semaglutide and tirzepatide are in a class of drugs called glucagon-like peptide-1 (GLP-1) agonists . These medications mimic GLP-1, a hormone made in the small intestine that helps lower blood sugar, decreases appetite, and makes a person feel fuller (satiety).

After the introduction of semaglutide as the diabetes medication Ozempic, its manufacturer, Novo Nordisk, gained FDA approval in 2021 for the drug to be sold under the brand name Wegovy, specifically as a treatment for chronic weight management. Two years later, the FDA gave Eli Lilly the go-ahead to market tirzepatide for chronic weight management under the name Zepbound.

The latest study findings were based on outcomes from patients prescribed either Ozempic or Mounjaro, because at the time of the study, tirzepatide had not yet been approved for weight loss.

While both drugs are GLP-1 agonists, tirzepatide has an extra ingredient that may explain its greater potency.

"The drug incorporates an additional gastrointestinal hormone [a GIP or glucose-dependent insulinotropic polypeptide receptor agonist] that impacts insulin sensitivity and brain signaling to aid with satiety," says Farah Husain, MD, the division chief of bariatric surgery at the University of Arizona College of Medicine Phoenix and the medical director at Banner University Medical Center. "The addition of the new hormone component is likely the reason it is performing superiorly."

Weighing the Pros and Cons

When it comes to selecting the medication that will best suit your needs, Dr. Husain recommends talking to your primary care provider and possibly seeing an obesity medicine specialist.

"It's very important to understand a patient's medical problems, other medications, allergies, and history to choose the appropriate medication," Husain says.

While both Ozempic and Mounjaro are self-administered in once-weekly injections, Dr. Kim notes that semaglutide now also comes in tablet form to be taken orally. Called Rybelsus , the medicine is approved as a diabetes treatment but may help with weight loss.

Adverse events related to the medications tirzepatide and semaglutide are very similar, according to Johanna Finkle, MD, an obstetrician and gynecologist with the University of Kansas Health System in Kansas City.

"The side effects are primarily nausea, vomiting, and constipation," she says, warning that in some cases these medications can cause slow gastric emptying, worsen certain GI conditions such as gastroparesis , and other rare but serious side effects .

Insurance coverage may also be a consideration. List prices for a one-month supply range from $936 to $1,023, according to 2023 data from Peterson KFF Health System Tracker.

Manufacturer coupons may be available to reduce costs.

Although the results were determined from a large population, the study authors stress that more work is needed to compare the effects of tirzepatide and semaglutide on other key end points, such as reduction of major cardiac events.

Editorial Sources and Fact-Checking

Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy . We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.

Sources

1. Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection for the Treatment of Adults With Type 2 Diabetes. Novo Nordisk . December 5, 2017.
2. FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes. Lilly . May 13, 2022.
3. Garvey W et al. Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: The STEP 5 Trial. Nature Medicine . October 10, 2022.
4. Jastreboff A et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine . June 4, 2022.
5. Rodriguez P et al. Semaglutide vs. Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine . July 8, 2024.
6. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. U.S. Food and Drug Administration . June 4, 2021.
7. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration . November 8, 2023.
8. Amin K et al. How Do Prices of Drugs for Weight Loss in the U.S. Compare With Peer Nations' Prices? Peterson KFF Health System Tracker . August 17, 2023.

Meet Our Experts See Our Editorial Policy Meet Our Health Expert Network

Don Rauf

Author

Don Rauf has been a freelance health writer for over 12 years and his writing has been featured in HealthDay, CBS News, WebMD, U.S. News & World Report, Mental Floss, United Press International (UPI), Health , and MedicineNet. He was previously a reporter for DailyRx.com where he covered stories related to cardiology, diabetes, lung cancer, prostate cancer, erectile dysfunction, menopause, and allergies. He has interviewed doctors and pharmaceutical representatives in the U.S. and abroad.

He is a prolific writer and has written more than 50 books, including Lost America: Vanished Civilizations , Abandoned Towns , and Roadside Attractions . Rauf lives in Seattle, Washington.

… See full bio See Our Editorial Policy Meet Our Health Expert Network